Increased activity of platelet-activating factor acetylhydrolase in low- density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia

European Journal of Clinical Investigation

Volumn 27, Issue 7, 1997, Pages 595-602

  Karabina, S A P ^a   Elisaf, M ^b   Bairaktari, E ^b   Tzallas, C ^b   Siamopoulos, K C ^b   Tselepis, A D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Familial hypercholesterolaemia; Low density lipoprotein subfractions; Lysophosphatidylcholine; Oxidation; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; COPPER ION; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; SPHINGOMYELIN;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPID OXIDATION; MALE; PRIORITY JOURNAL;

EID: 0030822866     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1570706.x     Document Type: Article

References (49)

1. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Vall D, eds. The metabolic basis of inherited disease, 6th edn. New York: McGraw-Hill, 1989;1215-50.
2. Motulsky AG. Genetic aspects of familial hypercholesterolemia and its diagnosis. Arteriosclerosis 1989;9 (suppl. 1):13-17.
3. Scientific Steering Committee. Risk of fatal heart disease in familial hypercholesterolemia. Br Med J 1991;303:893-6.
4. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991;11:290-7.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
6. Witzum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
7. Steinbrecher UP, Zhang H, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Rad Biol Med 1990;9:155-68.
8. Steinberg D, Witzum JL. Lipoproteins and atherogenesis: current concepts. JAMA 1990;264:3047-52.
9. Steinbrecher UP, Parthasarathy S, Leak DS, Witzum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;81:3883-7.
10. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992;90:1138-44.
11. Mangin EL, Kugiyama K, Nguy JH, Kerns SA, Henry PD. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res 1993;72:161-6.
12. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 1989;30:305-15.
13. Liapikos ThA, Antonopoulou S, Karabina S-AP, Tsoukatos DC, Demopoulos CA, Tselepis AD. Platelet-activating factor formation during oxidative modification of low density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta 1994;1212:353-60.
14. Tselepis AD, Pinckard RN. PAF-acetylhydrolase: A novel enzyme with biochemical and clinical interest. Clin Chem Enzyme Commun 1992;4:279-90.
15. Stemler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 1991;266:11095-103.
16. Karabina S-AP, Liapikos ThA, Grekas G, Goudevenos J, Tselepis A. Distribution of PAF-acetylhydrolase activity in human plasma low density lipoprotein subfractions. Biochim Biophys Acta 1994;1213:34-8.
17. Tselepis AD, Dentan C, Karabina S-AP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995;15:1764-73.
18. De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298-306.
19. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-49.
20. Williams RR, Schumacher MC, Barlow GK et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993;72:18D-24D.
21. Williams RR, Hunt SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6.
22. Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. Biochim Biophys Acta 1991;1081:65-74.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-17.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
25. Pinckard RN, Ludwig JC. Determination of PAF-2 acylhydrolase activity (abstract). Fed Proc 1986;45:856.
26. Esterbauer H, Gebicki J, Paul H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 1992;13:341-90.
27. Goudevenos J, Tselepis AD, Tsoukatos D, Grekas G, Kritikakos J, Sideris D. Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease. Eur Heart J 1995;16:1036-43.
28. Satoh K, Imaizumi T-A, Kawamura Y, Yoshida H, Takamatsu S, Mizono S. Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease. Prostaglandins 1988;35:685-98.
29. Hofmann B, Ruhling K, Spangenberg P, Ostermann G. Enhanced degradation of platelet-activating factor in serum from diabetic patients. Haemostasis 1989;19:180-4.
30. Tetta C, Bussolino F, Modena F et al. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1990;91:244-56.
31. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci USA 1989;86:2393-7.
32. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem 1987;262:4223-30.
33. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Am Assoc Physiol 1993;106:44-63.
34. Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 1991;266:11104-10.
35. Heery JM, Kozak M, Stafforini DM et al. Oxidatively modified LDL contains phospholipids with platelet activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995;96:2322-30.
36. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988;85:2805-9.
37. Kume N, Gimbrone MA, Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994;93:907-11.
38. Portman OW, Alexander M. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J Lipid Res 1969;10:158-65.
39. Sakai M, Miyazaki A, Hakamata H et al. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 1994;269:31430-5.
40. Ares MPS, Kallin B, Eriksson P, Nilson J. Oxidized LDL induces transcription factor activator protein-1 but inhibits activation of nuclear factor-kB in human vascular smooth muscle cells. Arterioscl Thromb Vasc Biol 1995;10:1584-90.
41. Dentan C, Lesnik P, Chapman MJ, Ninio E. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. Arterioscler Thromb 1994;14:353-60.
42. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Circulation 1989;79:8-15.
43. Parthasarathy S, Barnett J, Fong LG. High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83.
44. Watson AD, Navab M, Hama SY et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized-low density lipoprotein. J Clin Invest 1995;95:774-82.
45. Regenstrom J, Nilsson J, Tomvall P, Landou C, Hamsten A. Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-5.
46. Liu K, Cuddy TE, Pierce GN. Oxidative status of lipoproteins in coronary disease patients. Am Heart J 1992;123:285-9.
47. Guerin M, Dolphin PJ, Talussot C, Gardette J, Berthezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1359-68.
48. Raal FJ, Areias AJ, Waisberg R, von Arb M. Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolemia. Atherosclerosis 1995;115:9-15.
49. Cominacini L, Pastorino AM, Garbin U et al. The susceptibility of low-density lipoprotein to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition 1994;10:527-31.